Endologix, TriVascular Technologies Announce Merger
Endologix, a developer of minimally invasive treatments for aortic disorders has reached an agreement to merge with Santa Rosa, Calif.-based TriVascular Technologies in a cash and stock transaction valued at around $211 million.
TriVascular Technologies, a developer of technologies to advance minimally invasive treatment of abdominal aortic aneurysms, will become a wholly owned subsidiary of Endologix.
The combined company will conduct business as Endologix with its U.S. headquarters in Irvine, Calif., the location of Endologix’s current headquarters.
Endologix CEO John McDermott says the merger will help to provide physicians with three complementary products to treat a range of patient anatomies: AFX, Ovation and Nellix. — Michael Cipriano